We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

160 hedge funds and large institutions have $873M invested in Pacific Biosciences in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 41

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

8% more capital invested

Capital invested by funds: $809M → $873M (+$63.2M)

6.85% more ownership

Funds ownership: 73.1% → 79.95% (+6.9%)

3% more funds holding

Funds holding: 155 → 160 (+5)

73% less call options, than puts

Call options by funds: $1.19M | Put options by funds: $4.36M

Holders
160
Holders Change
+5
Holders Change %
+3.23%
% of All Funds
3.46%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
29
Increased
65
Reduced
41
Closed
23
Calls
$1.19M
Puts
$4.36M
Net Calls
-$3.17M
Net Calls Change
-$7.29M

Top Buyers

1
UOC
UBS O'Connor
Illinois
+$22.2M
2
Citadel Advisors
Citadel Advisors
Florida
+$19M
3
KLCMU
Kite Lake Capital Management (UK)
United Kingdom
+$18.7M
4
WIC
Water Island Capital
New York
+$16.3M
5
VI
Versor Investments
New York
+$15.2M

Top Sellers

1
CCM
Consonance Capital Management
New York
-$18.2M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$18M
3
Capital International Investors
Capital International Investors
California
-$15.4M
4
OIM
Oracle Investment Management
Connecticut
-$10.5M
5
MF
Magnetar Financial
Illinois
-$7.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
101
ProShare Advisors
Maryland
$479K +$10.3K +1,420 +2%
SCM
102
Stevens Capital Management
Pennsylvania
$469K -$1.95M -269,783 -81%
AG
103
Aperio Group
California
$458K +$110K +15,140 +31%
MIM
104
MetLife Investment Management
New Jersey
$417K – – –
VOYA Investment Management
105
VOYA Investment Management
Georgia
$405K – – –
WAM
106
Wolverine Asset Management
Illinois
$405K – – –
State Board of Administration of Florida Retirement System
107
State Board of Administration of Florida Retirement System
Florida
$377K – – –
GCP
108
GSA Capital Partners
United Kingdom
$357K +$357K +49,403 New
SO
109
STRS Ohio
Ohio
$318K – – –
T. Rowe Price Associates
110
T. Rowe Price Associates
Maryland
$298K +$2.89K +400 +1%
MLICM
111
Metropolitan Life Insurance Company (MetLife)
New York
$294K -$15.1K -2,088 -5%
Group One Trading
112
Group One Trading
Illinois
$286K -$179K -24,723 -38%
BNP Paribas Financial Markets
113
BNP Paribas Financial Markets
France
$255K +$255K +35,288 New
GC
114
Guggenheim Capital
Illinois
$231K +$231K +31,896 New
Mitsubishi UFJ Asset Management
115
Mitsubishi UFJ Asset Management
Japan
$219K +$5.3K +733 +2%
DekaBank Deutsche Girozentrale
116
DekaBank Deutsche Girozentrale
Germany
$213K +$61.5K +8,500 +23%
O
117
OppenheimerFunds
New York
$208K -$2.49M -343,969 -92%
USAA
118
United Services Automobile Association
Texas
$208K +$51.2K +7,076 +33%
Legal & General Group
119
Legal & General Group
United Kingdom
$196K +$5.15K +712 +3%
LWAC
120
Laurel Wealth Advisors (California)
California
$188K +$188K +26,000 New
HF
121
HRT Financial
New York
$176K +$177K +24,477 New
AB
122
Amalgamated Bank
New York
$149K +$5.19K +717 +4%
AF
123
Advisornet Financial
Minnesota
$147K – – –
LPL Financial
124
LPL Financial
California
$147K +$147K +20,350 New
Principal Financial Group
125
Principal Financial Group
Iowa
$139K -$121K -16,733 -47%
3 4
5
6 7

PACB Hedge Fund Activity: Q1 2019 in Review

160 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2019, worth a combined $873M — up 7.8% from $809M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PACB positions and 23 closed out — a net gain of 6 holders — while 65 added to existing stakes and 41 trimmed.

The largest buyer was UBS O'Connor, adding an estimated $22.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $18.2M sold.

  • 160 institutional investors held Pacific Biosciences (PACB) as of Q1 2019, up from 155 in Q4 2018.
  • Funds reported $873M of Pacific Biosciences stock for Q1 2019, up 7.8% quarter-over-quarter.
  • 29 funds opened new Pacific Biosciences positions in Q1 2019 and 23 closed out, a net change of +6 holders.
  • The largest Pacific Biosciences buyer in Q1 2019 was UBS O'Connor, an estimated $22.2M added.
  • The largest Pacific Biosciences seller in Q1 2019 was Consonance Capital Management, an estimated $18.2M sold.

Based on aggregated 13F filings for Q1 2019.